• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
HE Siyu, SUN Haopeng. Advances of covalently modified drugs[J]. Journal of China Pharmaceutical University, 2017, 48(5): 503-514. DOI: 10.11665/j.issn.1000-5048.20170501
Citation: HE Siyu, SUN Haopeng. Advances of covalently modified drugs[J]. Journal of China Pharmaceutical University, 2017, 48(5): 503-514. DOI: 10.11665/j.issn.1000-5048.20170501
shu

Advances of covalently modified drugs

More Information
    Graphical Abstract
    • Abstract
  • Covalently modified drugs, which exert their pharmacological effects by covalently binding to the targets, have been avoided as far as possible for a long time in drug design due to the potential off-target effects and other side-effects. With the in-depth study of binding modes of market blockbuster covalent drugs, more and more attention has been concentrated on covalently modified drugs. Current challenges remain in development of potent selective covalently modified drugs with fewer adverse effects. This paper reviews the classification of some covalently modified drugs, the drug-target binding modes and the new strategies of designing covalently modified drugs, in order to provide reference for rational design of covalent drugs.
    • FullText(HTML)
    • References (43)
  • [1]
    Singh J,Petter RC,Baillie TA,et al.The resurgence of covalent drugs[J].Nat Rev Drug Discov,2011,10(4):307-317.
    [2]
    Bauer RA.Covalent inhibitors in drug discovery:from accidental discoveries to avoided liabilities and designed therapies[J].Drug Discov Today,2015,20(9):1061-1073.
    [3]
    Barf T,Kaptein A.Irreversible protein kinase inhibitors:balancing the benefits and risks[J].J Med Chem,2012,55(14):6243-6262.
    [4]
    Baillie TA. Targeted covalent inhibitors for drug design[J].Angew Chem Int Ed Engl,2016,55(43):13408-13421.
    [5]
    Hossam M,Lasheen DS,Abouzid KA.Covalent EGFR inhibitors:binding mechanisms,synthetic approaches,and clinical profiles[J].Arch Pharm(Weinheim),2016,349(8):573-593.
    [6]
    Cheng H,Nair SK,Murray BW.Recent progress on third generation covalent EGFR inhibitors[J].Bioorg Med Chem Lett,2016,26(8):1861-1868.
    [7]
    Akinleye A,Chen YM,Mukhi N,et al.Ibrutinib and novel BTK inhibitors in clinical development[J].J Hematol Oncol,2013,6(1):1-9.
    [8]
    Woyach JA,Furman RR,Liu TM,et al.Resistance mechanisms for the Bruton′s tyrosine kinase inhibitor Ibrutinib[J].New Engl J Med,2014,370(24):2286-2294.
    [9]
    Harrington BK,Gulrajani M,Covey T,et al.ACP-196 is a second generation inhibitor of Bruton tyrosine kinase(BTK)with enhanced target specificity[J].Blood,2015,126(23):2908.
    [10]
    Wu J,Liu C,Tsui ST,et al.Second-generation inhibitors of Bruton tyrosine kinase[J].J Hematol Oncol,2016,9(1):80.
    [11]
    Park JK,Byun JY,Park JA,et al.HM71224,a novel Bruton′s tyrosine kinase inhibitor,suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model:a potential drug for rheumatoid arthritis[J].Arthritis Res Ther,2016,18(1):1-9.
    [12]
    Hagel M,Miduturu C,Sheets M,et al.First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway[J].Cancer Discov,2015,5(4):424-437.
    [13]
    Ihle NT,Williams R,Chow S,et al.Molecular pharmacology and antitumor activity of PX-866,a novel inhibitor of phosphoinositide-3-kinase signaling[J].Mol Cancer Ther,2004,3(7):763-772.
    [14]
    Zhao Y,Adjei AA.The clinical development of MEK inhibitors[J].Nat Rev Clin Oncol,2014,11(7):385-400.
    [15]
    Zhang J,Wu P,Hu Y.Clinical and marketed proteasome inhibitors for cancer treatment[J].Curr Med Chem,2013,20(20):2537-2551.
    [16]
    Groll M,Berkers CR,Ploegh HL,et al.Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome[J].Structure,2006,14(3):451-456.
    [17]
    Accardi F,Toscani D,Bolzoni M,et al.Mechanism of action of Bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment:impact on myeloma-induced alterations of bone remodeling[J].Biomed Res Int,2015,2015(2):1-13.
    [18]
    Kisselev AF, van der Linden WA, Overkleeft HS. Proteasome inhibitors:an expanding army attacking a unique target[J].Chem Biol,2012,19(1):99-115.
    [19]
    Hadvary P,Sidler W,Meister W,et al.The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase[J].J Biol Chem,1991,266(4):2021-2027.
    [20]
    Nabeno M,Akahoshi F,Kishida H,et al.A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site[J].Biochem Biophs Res Commun,2013,434(2):191-196.
    [21]
    Fura A,Khanna A,Vyas V,et al.Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats,dogs,and monkeys and clinical projections[J].Drug Metab Dispos,2009,37(6):1164-1171.
    [22]
    Bone HG,Dempster DW,Eisman JA,et al.Odanacatib for the treatment of postmenopausal osteoporosis:development history and design and participant characteristics of LOFT,the long-term odanacatib fracture trial[J].Osteoporos Int,2015,26(2):699-712.
    [23]
    Wilson AJ,Kerns JK,Callahan JF,et al.Keap calm,and carry on covalently[J].J Med Chem,2013,56(19):7463-7476.
    [24]
    Linker RA,Lee DH,Ryan S,et al.Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway[J].Brain,2011,134(3):678-692.
    [25]
    Cleasby A,Yon J,Day PJ,et al.Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO[J].PLoS ONE,2014,9(6):e98896.
    [26]
    Probst BL,Trevino I,Mccauley L,et al.RTA 408,A novel synthetic triterpenoid with broad anticancer and anti-inflammatory activity[J].PLoS ONE,2015,10(4):e0122942.
    [27]
    Li W,Zheng S,Higgins M,et al.New monocyclic,bicyclic,and tricyclic ethynylcyanodienones as activators of the Keap1/Nrf2/ARE pathway and inhibitors of inducible nitric oxide synthase[J].J Med Chem,2015,58(11):4738-4748.
    [28]
    Huerta C,Jiang X,Trevino I,et al.Characterization of novel small-molecule NRF2 activators:structural and biochemical validation of stereospecific KEAP1 binding[J].Biochimica Et Biophysica Acta,2016,1860(11):2537-2552.
    [29]
    Doyle K,Lönn H,Käck H,et al.Discovery of second generation reversible covalent DPP1 inhibitors leading to an oxazepane amidoacetonitrile based clinical candidate(AZD7986)[J].J Med Chem,2016,59(20):9457-9472.
    [30]
    Ahn K,Smith SE,Liimatta MB,et al.Mechanistic and pharmacological characterization of PF-04457845:a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain[J].J Pharmaco Exp Ther,2011,338(1):114-124.
    [31]
    Joharapurkar AA, Dhanesha NA, Jain MR. Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity[J].Diabetes Metab Syndr Obes,2014,7:73-84.
    [32]
    Butler KV,Ma A,Yu W,et al.Structure-based design of a covalent inhibitor of the SET domain-containing protein 8(SETD8)lysine methyltransferase[J].J Med Chem,2016,59(21):9881-9889.
    [33]
    Zhang Y,Zhang D,Tian H,et al.Identification of covalent binding sites targeting cysteines based on computational approaches[J].Mol Pharm,2016,13(9):3106-3118.
    [34]
    Schreiber SL,Kotz JD,Li M,et al.Advancing biological understanding and therapeutics discovery with small-molecule probes[J].Cell,2015,161(6):1252-1265.
    [35]
    Lanning BR,Whitby LR,Dix MM,et al.A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors[J].Nat Chem Biol,2014,10(9):760-767.
    [36]
    Backus KM,Correia BE,Lum KM,et al.Proteome-wide covalent ligand discovery in native biological systems[J].Nature,2016,534(7608):570-574.
    [37]
    Chen YC,Zhang C.A chemoproteomic method for identifying cellular targets of covalent kinase inhibitors[J].Genes Cancer,2016,7(5/6):148-153.
    [38]
    Jost C,Nitsche C,Scholz T,et al.Promiscuity and selectivity in covalent enzyme inhibition:a systematic study of electrophilic fragments[J].J Med Chem,2014,57(18):7590-7599.
    [39]
    Becker D,Kaczmarska Z,Arkona C,et al.Irreversible inhibitors of the 3C protease of Coxsackie virus through templated assembly of protein-binding fragments[J].Nat Commun,2016,7:12761.
    [40]
    Kumalo HM,Bhakat S,Soliman ME.Theory and applications of covalent docking in drug discovery:merits and pitfalls[J].Molecules,2015,20(2):1984-2000.
    [41]
    Toledo Warshaviak D,Golan G,Borrelli KW,et al.Structure-based virtual screening approach for discovery of covalently bound ligands[J].J Chem Inf Model,2014,54(7):1941-1950.
    [42]
    Schroder J,Klinger A,Oellien F,et al.Docking-based virtual screening of covalently binding ligands:an orthogonal lead discovery approach[J].J Med Chem,2013,56(4):1478-1490.
    [43]
    Schirmeister T,Kesselring J,Jung S,et al.Quantum chemical-based protocol for the rational design of covalent inhibitors[J].J Am Chem Soc,2016,138(27):8332-8335.
    • Related Articles

  • Related Articles

    [1]SHANG Feiyang, LIU Chengbo, TAN Hongzhou, HE Bing, HE Liqin. Design, synthesis and antiplatelet aggregation activity of 3-acetyl-7-hydroxycoumarin derivatives[J]. Journal of China Pharmaceutical University, 2024, 55(3): 367-374. DOI: 10.11665/j.issn.1000-5048.2023072901
    [2]HU Yuheng, SUN Jie, YANG Jie, WANG Xiaojing. Synthesis and in vitro hypoglycemic activity of 3-(4′-benzoyl amino-phenyl)-coumarin derivatives[J]. Journal of China Pharmaceutical University, 2019, 50(2): 168-174. DOI: 10.11665/j.issn.1000-5048.20190206
    [3]YANG Guoxun, XIONG Juan, HU Jinfeng. 2017′s advanced natural products chemistry researches in China(2)[J]. Journal of China Pharmaceutical University, 2018, 49(6): 637-645. DOI: 10.11665/j.issn.1000-5048.20180601
    [4]YANG Guoxun, XIONG Juan, HU Jinfeng. 2017′s advanced natural products chemistry researches in China(1)[J]. Journal of China Pharmaceutical University, 2018, 49(5): 511-520. DOI: 10.11665/j.issn.1000-5048.20180501
    [5]YANG Rui, ZHU Yi, WANG Yin, MA Wenqi, WANG Xin, HAN Xiqiong, LIU Naifeng. Recent progress in autophagy and vascular calcification[J]. Journal of China Pharmaceutical University, 2018, 49(4): 401-406. DOI: 10.11665/j.issn.1000-5048.20180403
    [6]JIN Yue, WU Xuri, CHEN Yijun. Applications of glycosyltransferases in the improvement of druggability of natural products[J]. Journal of China Pharmaceutical University, 2017, 48(5): 529-535. DOI: 10.11665/j.issn.1000-5048.20170504
    [7]YU Sulan, YU Xiu, KOU Junping. Advances in the mechanism research of natural products against acute lung injury[J]. Journal of China Pharmaceutical University, 2016, 47(4): 397-403. DOI: 10.11665/j.issn.1000-5048.20160403
    [8]XIANG Min, ZHANG Yaqin, WU Pingping, GAO Zhenyu. Effect of block of AGEs-RAGE pathway on the migration of VSMCs[J]. Journal of China Pharmaceutical University, 2016, 47(2): 199-203. DOI: 10.11665/j.issn.1000-5048.20160212
    [10]YANG Ya-Bo, WANG Min, LIANG Yan, LIANG Jing-Yu. Transgalactosylation of Isotaxiresinol by[J]. Journal of China Pharmaceutical University, 2002, (6).

Catalog

    Get Citation
    PDF
    XML
    Article views (1376) PDF downloads (4595) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：292672

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return